IRVINE, Calif.--(BUSINESS WIRE)--Khang & Khang LLP (the “Firm”) announces a class action lawsuit has been filed against American Renal Associates Holdings, Inc. (“ARA” or the “Company”) (NYSE: ARA). Investors who purchased or otherwise acquired shares 1) pursuant and/or traceable to the Initial Public Offering (“IPO”) on or about April 21, 2016; and/or 2) on the open market between April 21, 2016 and August 18, 2016 (the “Class Period”), should contact the Firm in advance of the October 31, 2016 lead plaintiff motion deadline.
If you purchased ARA shares during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: 949-419-3834, or by e-mail at email@example.com.
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
The complaint alleges that throughout the Class Period, ARA issued false and misleading statements to investors and/or failed to disclose that: the Company was engaged in a fraudulent scheme to steer patients away from Medicare and Medicaid plans they qualified for into more expensive Affordable Care Act plans to obtain greater reimbursement for its dialysis services; the scheme was in violation of federal and state laws; and as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. When this information was disclosed, shares of ARA dropped in value, causing investors harm.
If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: 949-419-3834, or by e-mail at firstname.lastname@example.org.
This press release may constitute Attorney Advertising in some jurisdictions.